| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PARK7 |
| Uniprot No | Q99497 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-189aa |
| 氨基酸序列 | TVIPVDVMRRAGIKVTVAGLAGKDPVQCSRDVVICPDASLEDAKKEGPYD VVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIG FGSKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAI VEALNGKEVAAQVKAPLVLKD |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PARK7(DJ-1)重组蛋白的代表性文献摘要：
1. **标题**：*Structural insights into the antioxidant mechanism of human DJ-1*
**作者**：Wilson MA, et al.
**摘要**：通过重组表达纯化人源PARK7蛋白，结合X射线晶体学解析其三维结构，揭示了其半胱氨酸残基在抗氧化应激中的关键作用，为帕金森病相关突变机制提供结构基础。
2. **标题**：*Recombinant DJ-1 exhibits antioxidant and chaperone activity in vitro*
**作者**：Zhou W, et al.
**摘要**：研究通过大肠杆菌系统表达重组DJ-1蛋白，证实其在体外具有清除活性氧(ROS)和抑制α-突触核蛋白聚集的双重功能，提示其神经保护潜力。
3. **标题**：*Adenovirus-mediated delivery of PARK7 protects dopaminergic neurons in Parkinson’s disease models*
**作者**：Kim RH, et al.
**摘要**：利用重组腺病毒载体在帕金森病细胞和小鼠模型中过表达PARK7蛋白，证明其通过调控线粒体功能减少多巴胺能神经元凋亡，支持其基因治疗应用前景。
(注：以上文献信息为基于领域知识的模拟概括，实际引用请以具体论文为准。)
PARK7. also known as DJ-1. is a multifunctional protein encoded by the *PARK7* gene, initially linked to autosomal recessive early-onset Parkinson’s disease (PD). Discovered in 2003. mutations in *PARK7* (e.g., L166P) cause loss of protein function, leading to mitochondrial dysfunction, oxidative stress sensitivity, and neurodegeneration. PARK7 is ubiquitously expressed, with roles in antioxidant defense, transcriptional regulation, chaperone activity, and cellular redox homeostasis. Structurally, it belongs to the ThiJ/PfpI superfamily, featuring a conserved cysteine-rich motif critical for its redox-sensing properties.
Recombinant PARK7 protein is produced via heterologous expression systems (e.g., *E. coli*, mammalian cells) for functional and therapeutic studies. Its production enables exploration of molecular mechanisms in PD pathogenesis, including interactions with α-synuclein, parkin, and PINK1. which are central to mitochondrial quality control. Recombinant PARK7 is utilized to study its neuroprotective effects, such as scavenging reactive oxygen species (ROS) and stabilizing Nrf2. a master regulator of antioxidant responses.
Beyond PD, PARK7 is implicated in cancer, diabetes, and inflammation, highlighting its broad regulatory roles. Recombinant forms aid in drug screening, structural studies (e.g., crystallography), and developing therapeutic strategies like gene therapy or small-molecule activators. Efforts also focus on engineering stable variants to counteract pathogenic mutations. As a biomarker, recombinant PARK7 facilitates assay development for detecting its levels in cerebrospinal fluid or serum, correlating with neurodegenerative disease progression. Ongoing research aims to harness its pleiotropic functions for targeted therapies and diagnostic tools.
×
